Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar - CNBC
- Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar CNBC
- Eli Lilly raises annual profit forecast as Zepbound quarterly sales cross $1 billion Yahoo Finance
- Eli Lilly Lifts 2024 Sales Outlook as Zepbound Demand Drives Quarter Bloomberg
- Eli Lilly’s stock leaps after big earnings beat, boosted by strength in Mounjaro and Zepbound sales MarketWatch